Fig 8. A model for the palliative effect of oral administration of BBG9-1 against RV gastroenteritis.

Oral administration of BBG9-1 induced mucosal protective factors, such as mucin, TFF3 and TGFβ1. Acidic mucins neutralize RV infection and replication in the small intestine. Mucosal protective factors coordinately protect against damage after RV infection to alleviate decreased gene expression of SGLT-1, which plays a pivotal role in water absorption. Orally administered BBG9-1 replicates in the large intestine to assimilate undigested nutrients, contributing to reduction in osmotic pressure. Improvement in water malabsorption in both the small and large intestines contributes to alleviation of RV-induced diarrhea.